Our results suggest a possible regulatory mechanism of the tumor immune microenvironment associated with low-EPAS1 expression in AML, which may be helpful to the development of immunotherapy for AML patients in the future. The gene discussed is EPAS1; the disease is acute myeloid leukemia.